Champions Oncology, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $68.9M
- Price
- $4.96
- % Change (Daily % change from the live per-ticker quote feed.)
- -4.25%
- Volume
- 8.2K
About
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.
Quick stats
Shares outstanding13.9M
Computed float5.1M
Float / shares36.4%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000771856
AI Summary
AI-generated1/8
standardbullishearnings
Champions Oncology Reports Record Annual Revenue of $59 Million
Champions Oncology reported fiscal 2026 annual revenue of $59.4 million, a 4% year-over-year increase, achieving record fourth-quarter revenue of $13.8 million, up 12%.
The company delivered positive Adjusted EBITDA of $158,000 in the fourth quarter and $1.6 million for the full year, marking four consecutive quarters of positive Adjusted EBITDA.
Oncology services margins expanded to 51% in Q4 from 41% a year ago, driven by cost discipline and the transition of radiopharmaceutical activities in-house.
Red flags
- GAAP net income swung to a loss of $1.2 million from a prior year profit of $4.7 million
- Cash position decreased from $9.8 million to $4.9 million over the fiscal year